Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Wenzhou Medical University currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is assigned to 1 distinct examiner and 1 distinct art unit. This suggests a narrow focus for the university's current pending patent applications.
The busiest examiner for the university is STEELE, AMBER D, who is responsible for 1 busiest examiner pending action. This 1 examiner is the official currently reviewing the university's pending workload. Practitioners should analyze the past decisions of this 1 individual in the Biotechnology & Pharmaceuticals sector to better prepare for the 1 pending office action.
The involvement of 1 distinct art unit simplifies the prosecution landscape. There is no need to coordinate between different art units with different standards. The university's current efforts are concentrated on the 1 pending office action within the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17768296 | FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR)-TARGETING ANTAGONISTIC SHORT PEPTIDE | STEELE, AMBER D | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17768296 | FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR)-TARGETING ANTAGONISTIC SHORT PEPTIDE | STEELE, AMBER D | 1658 | §102§103 | Non-Final OA | — | Pending | Apr 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWenzhou Medical University has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amber D Steele has the most, with 1 of Wenzhou Medical University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
